2013
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice
Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2013, 6: 249-269. PMID: 23656339, PMCID: PMC4198941, DOI: 10.1586/ecp.13.18.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAntiretroviral therapyDrug interactionsAgonist therapyHIV medicationsHepatitis C virus medicationsHepatitis C virus (HCV) treatmentActive antiretroviral therapyC virus treatmentPharmacodynamic drug interactionsImportant clinical consequencesReview of abstractsHCV therapyAntiretroviral agentsPharmacodynamic interactionsPharmacological interactionsHIV therapyClinical consequencesVirus treatmentClinical practiceFollowing keywordsTherapyClinical implicationsMedicationsMethadone
2008
Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia
Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL. Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia. The American Journal Of Drug And Alcohol Abuse 2008, 34: 511-517. PMID: 18584580, DOI: 10.1080/00952990802122259.Peer-Reviewed Original ResearchConceptsBuprenorphine injectionBuprenorphine injectorsCase seriesSignificant adverse health consequencesProspective cohort studyPossible pharmacological interactionsAdverse health consequencesDiversion of buprenorphineCohort studyResultant symptomsPoor outcomeCase reportTreatment modalitiesPharmacological interactionsBuprenorphineEuphoric effectsHealth consequencesKuala LumpurMidazolamInjectionQualitative interviewsSymptoms